CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other EventsItem 8.01. Other Events
On November7, 2017, CRISPR Therapeutics AG (the “Company”) issued a press release announcing that the Company will present data on November 10, 2017 at 6:00 PM eastern at the Society for Immunotherapy of Cancer (“SITC”) 32nd Annual Conference. A live webcast of the presentation, and the presentation materials, can be accessed under “Events& Presentations” in the Investors& Media section of the Company’s website at www.crisprtx.com. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 8.01. Financial Statements and Exhibits.
(d)Exhibits:
CRISPR Therapeutics AG ExhibitEX-99.1 2 d489475dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting ZUG,…To view the full exhibit click here
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
